FDA clears antidepressant use of Abilify

11/20/2007 | Forbes

Bristol-Myers Squibb Co.'s schizophrenia drug Abilify has been approved by the FDA for use as an additional antidepressant treatment for people with major depressive disorder. The decision follows a clinical trial involving 743 patients. The drug is co-marketed by Otsuka Pharmaceutical Co.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC